



# Hospitalizations for Chronic Obstructive Pulmonary Disease Exacerbation During COVID-19

Arnaud Bourdin, MD, PhD; Engi Ahmed, MD, PhD; Isabelle Vachier, MD, PhD; Nicolas Roche, MD, PhD; Joana Pissarra, PhD; Nicolas Malafaye, MSc; Nicolas Molinari, PhD

## Introduction

The extent to which airborne infections trigger chronic obstructive pulmonary disease (COPD) exacerbations is debated.<sup>1</sup> Bacteria, air pollution, heart failure, and other causes worsen COPD symptoms and precipitate unscheduled medical care. Extensive data show that bacterial and viral infections stimulate inflammation, thereby inducing exacerbations.<sup>2,3</sup> Seasonal peaks are a hallmark characteristic of COPD exacerbations and viral infections, such as influenza or colds, further supporting their association.<sup>4</sup>

Clinicians and patients experienced this seasonality until 2020, when the COVID-19 pandemic began. Remembering the possible contribution of respiratory viruses to onset of COPD exacerbations, we investigated the number of COPD-related admissions before, during, and after the COVID-19 pandemic.

## Methods

This retrospective cross-sectional study is based on French National Health Data System data (eMethods in [Supplement 1](#)). An algorithm based on *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)* codes extracted COPD exacerbations in any hospital admission in France from January 1, 2013, to July 31, 2023. An interrupted time series analysis (ITSA) used the R package *its.analysis*, version 4.3.1, to model the association of preventive measures with COPD admissions and linear regression for graphic representation only. According to French law, this anonymous retrospective observational database study did not require ethics committee approval or patient informed consent. We followed the [STROBE](#) reporting guideline. Two-sided statistical tests indicated significance at  $P < .05$ .

## Results

Of 800 730 patients (1 393 825 admissions), mean (SD) age was 74.4 (12.5) years; 62.5% were male and 37.5 were female. Prevalence of relevant comorbidities included 63.5% hypertension, 43.2% heart failure, 6.9% lung cancer, and 2.4% bladder cancer. Prior to COVID-19, the seasonality of hospital and intensive care unit stays for COPD exacerbations showed a distinct pattern, with single or double peaks during fall and winter (**Figure**). In March 2020, COPD exacerbations plummeted at the initiation of COVID-19 lockdowns and remained low until late 2021. This reduction occurred immediately after the introduction of infection transmission protective measures (social distancing, masks, and extensive hand hygiene). In 2022, viral transmission preventive measures were less strict. An increasing but still reduced number of COPD exacerbations was recorded in June and July and winter of 2022. Once the World Health Organization declared the pandemic over in May 2023 and people abandoned widespread infection prevention measures, the seasonal peak in COPD exacerbations returned to its usual magnitude. The ITSA confirmed these observations and showed

## + Supplemental content

Author affiliations and article information are listed at the end of this article.

**Open Access.** This is an open access article distributed under the terms of the CC-BY License.


significant variation between periods for severe ( $F = 5.081$ ;  $P = .008$ ) and mild ( $F = 3.850$ ;  $P = .02$ ) cases (Table).

### Discussion

The association between COPD exacerbations and preventive measures questions the role airborne infections play in provoking COPD exacerbations. Other known risk factors were also decreased during the pandemic (eg, small particulate matter levels were reduced<sup>5</sup>), and a single underlying cause behind COPD exacerbations is unlikely. Nevertheless, the “on-off-on” outcome of protective measures showed how epidemiology can provide evidence mimicking a gene knockout-rescue model. Patients with COPD reported strongly adhering to such measures,<sup>6</sup> thereby reducing their exposure to airborne viruses. These data show that the implementation of infection transmission preventive measures overlaps the drop in COPD exacerbations, and the recirculation of seasonal viruses matches the return of COPD exacerbations, corroborating the involvement of viral infection in COPD exacerbations.

Study limitations include the lack of individual clinical information in the national registry and no direct comparison with the number of diagnosed viral infections. Relevant data on demographic characteristics and comorbidities confirm that the patients’ profiles align with what is expected in a population with COPD.

Figure. Nationwide Number of Admissions for Chronic Obstructive Pulmonary Disease (COPD) Exacerbations



Gray shading indicates the official beginning and end of the social distancing measures enforcement. Dashed lines indicate the linear trend for each period (before, during, and after implementation of preventive measures due to the COVID-19 pandemic). ICU indicates intensive care unit.

Table. COPD Admissions by Severity and ITSA Results

| Case severity | COPD admissions, mean (SD)   |                              |                             | ITSA modeling output |         |         |                               |
|---------------|------------------------------|------------------------------|-----------------------------|----------------------|---------|---------|-------------------------------|
|               | Before COVID-19 <sup>a</sup> | During COVID-19 <sup>b</sup> | After COVID-19 <sup>c</sup> | Sum of squares       | F value | P value | Bootstrapped F value (95% CI) |
| Mild          | 10 122 (2256)                | 7010 (1127)                  | 8862 (2068)                 | 17 922 979           | 3.850   | .02     | 4.231 (1.129-10.682)          |
| Severe        | 1971 (411)                   | 1385 (154)                   | 1780 (404)                  | 828 753              | 5.081   | .008    | 5.524 (1.696-13.403)          |

Abbreviations: COPD, chronic obstructive pulmonary disease; ITSA, interrupted time series analysis.

<sup>b</sup> From March 16, 2020, to March 15, 2022.

<sup>c</sup> From March 16, 2022, to July 31, 2023.

<sup>a</sup> From January 1, 2013, to March 15, 2020.

These data support the use of individual protective measures during winter by patients with COPD and their relatives and caregivers. The graph line (Figure) becomes a starting point for describing the underlying mechanisms behind exacerbations and their relative contributions, and the debate around viral infections triggering COPD exacerbations may be finally settled.

## ARTICLE INFORMATION

**Accepted for Publication:** March 19, 2024.

**Published:** May 21, 2024. doi:[10.1001/jamanetworkopen.2024.12383](https://doi.org/10.1001/jamanetworkopen.2024.12383)

**Open Access:** This is an open access article distributed under the terms of the [CC-BY License](https://creativecommons.org/licenses/by/4.0/). © 2024 Bourdin A et al. *JAMA Network Open*.

**Corresponding Author:** Arnaud Bourdin, MD, PhD, Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, 34090 Montpellier, France ([a-bourdin@chu-montpellier.fr](mailto:a-bourdin@chu-montpellier.fr)).

**Author Affiliations:** Department of Respiratory Diseases, University of Montpellier, Centre Hospitalier Universitaire (CHU) Montpellier, Montpellier, France (Bourdin, Ahmed, Vachier); Laboratoire de Physiologie et Médecine Expérimentale du Cœur et des Muscles, University of Montpellier, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Montpellier, Montpellier, France (Bourdin, Ahmed, Vachier); Laboratory of Immunoregulation and Mucosal Immunology, VIB-UGent Center for Inflammation Research, Ghent, Belgium (Ahmed); Assistance Publique-Hôpitaux de Paris, Centre-Université Paris Cité, Cochin Hospital and Institute (INSERM UMR1016), Respiratory Medicine, Paris, France (Roche); Clinical Research and Epidemiology Unit, CHU Montpellier, University of Montpellier, Montpellier, France (Pissarra, Malafaye); Institut Desbrest d'Épidémiologie et de Santé Publique, INSERM, Precision Medicine by Data Integration and Causal Learning, Institut National de Recherche en Informatique et en Automatique, University of Montpellier, CHU Montpellier, Montpellier, France (Molinari).

**Author Contributions:** Dr Bourdin had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

*Concept and design:* Bourdin, Vachier, Malafaye, Molinari.

*Acquisition, analysis, or interpretation of data:* Bourdin, Ahmed, Roche, Pissarra, Malafaye, Molinari.

*Drafting of the manuscript:* Bourdin, Roche, Pissarra, Molinari.

*Critical review of the manuscript for important intellectual content:* All authors.

*Statistical analysis:* Molinari.

*Administrative, technical, or material support:* Bourdin, Vachier, Molinari.

*Supervision:* Bourdin, Molinari.

**Conflict of Interest Disclosures:** Dr Bourdin reported receiving grant funding from AstraZeneca and GSK PLC; personal fees from GSK PLC, AstraZeneca, Novartis AG, Chiesi Farmaceutici SpA, Sanofi SA, and Celltrion Inc; and nonfinancial support from Sanofi SA and Boehringer Ingelheim outside the submitted work. Dr Ahmed reported receiving personal financial support for lectures and attending meetings from Sanofi SA and AstraZeneca. Dr Roche reported receiving grant funding from Boehringer Ingelheim, Novartis AG, Pfizer Inc, and GSK PLC and personal fees from Boehringer Ingelheim, Novartis AG, Pfizer Inc, GSK PLC, Austral Pharma, Biosency, MSD, AstraZeneca, Chiesi Farmaceutici SpA, Menarini Group, Nuvaira, Sanofi SA, and Zambon outside the submitted work. No other disclosures were reported.

**Data Sharing Statement:** See [Supplement 2](#).

## REFERENCES

1. Linden D, Guo-Parke H, Coyle PV, et al. Respiratory viral infection: a potential "missing link" in the pathogenesis of COPD. *Eur Respir Rev*. 2019;28(151):180063. doi:[10.1183/16000617.0063-2018](https://doi.org/10.1183/16000617.0063-2018)
2. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. *N Engl J Med*. 2008;359(22):2355-2365. doi:[10.1056/NEJMra0800353](https://doi.org/10.1056/NEJMra0800353)
3. Mallia P, Message SD, Gielen V, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. *Am J Respir Crit Care Med*. 2011;183(6):734-742. doi:[10.1164/rccm.201006-0833OC](https://doi.org/10.1164/rccm.201006-0833OC)
4. Rabe KF, Fabbri LM, Vogelmeier C, et al. Seasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD trial. *Chest*. 2013;143(3):711-719. doi:[10.1378/chest.12-1277](https://doi.org/10.1378/chest.12-1277)

5. Lara R, Megido L, Suárez-Peña B, et al. Impact of COVID-19 restrictions on hourly levels of PM10, PM2.5 and black carbon at an industrial suburban site in northern Spain. *Atmos Environ (1994)*. 2023;304:119781. doi:10.1016/j.atmosenv.2023.119781
6. Kahnert K, Lutter JI, Welte T, et al. Impact of the COVID-19 pandemic on the behaviour and health status of patients with COPD: results from the German COPD cohort COSYCONET. *ERJ Open Res*. 2021;7(3):00242-2021. doi:10.1183/23120541.00242-2021

**SUPPLEMENT 1.****eMethods.** Data Accrual and Analysis**eReferences****SUPPLEMENT 2.****Data Sharing Statement**